Literature DB >> 21325596

Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions.

Samuel Quentin1, Wendy Cuccuini, Raphael Ceccaldi, Olivier Nibourel, Corinne Pondarre, Marie-Pierre Pagès, Nadia Vasquez, Catherine Dubois d'Enghien, Jérôme Larghero, Régis Peffault de Latour, Vanderson Rocha, Jean-Hugues Dalle, Pascale Schneider, Mauricette Michallet, Gérard Michel, André Baruchel, François Sigaux, Eliane Gluckman, Thierry Leblanc, Dominique Stoppa-Lyonnet, Claude Preudhomme, Gérard Socié, Jean Soulier.   

Abstract

Fanconi anemia (FA) is a genetic condition associated with bone marrow (BM) failure, myelodysplasia (MDS), and acute myeloid leukemia (AML). We studied 57 FA patients with hypoplastic or aplastic anemia (n = 20), MDS (n = 18), AML (n = 11), or no BM abnormality (n = 8). BM samples were analyzed by karyotype, high-density DNA arrays with respect to paired fibroblasts, and by selected oncogene sequencing. A specific pattern of chromosomal abnormalities was found in MDS/AML, which included 1q+ (44.8%), 3q+ (41.4%), -7/7q (17.2%), and 11q- (13.8%). Moreover, cryptic RUNX1/AML1 lesions (translocations, deletions, or mutations) were observed for the first time in FA (20.7%). Rare mutations of NRAS, FLT3-ITD, MLL-PTD, ERG amplification, and ZFP36L2-PRDM16 translocation, but no TP53, TET2, CBL, NPM1, and CEBPα mutations were found. Frequent homozygosity regions were related not to somatic copy-neutral loss of heterozygosity but to consanguinity, suggesting that homologous recombination is not a common progression mechanism in FA. Importantly, the RUNX1 and other chromosomal/genomic lesions were found at the MDS/AML stages, except for 1q+, which was found at all stages. These data have implications for staging and therapeutic managing in FA patients, and also to analyze the mechanisms of clonal evolution and oncogenesis in a background of genomic instability and BM failure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325596     DOI: 10.1182/blood-2010-09-308726

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  67 in total

1.  Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells.

Authors:  Raphael Ceccaldi; Kalindi Parmar; Enguerran Mouly; Marc Delord; Jung Min Kim; Marie Regairaz; Marika Pla; Nadia Vasquez; Qing-Shuo Zhang; Corinne Pondarre; Régis Peffault de Latour; Eliane Gluckman; Marina Cavazzana-Calvo; Thierry Leblanc; Jérôme Larghero; Markus Grompe; Gérard Socié; Alan D D'Andrea; Jean Soulier
Journal:  Cell Stem Cell       Date:  2012-06-07       Impact factor: 24.633

Review 2.  Genetic predisposition syndromes: when should they be considered in the work-up of MDS?

Authors:  Daria V Babushok; Monica Bessler
Journal:  Best Pract Res Clin Haematol       Date:  2014-11-12       Impact factor: 3.020

Review 3.  Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.

Authors:  Christen L Ebens; Margaret L MacMillan; John E Wagner
Journal:  Expert Rev Hematol       Date:  2016-12-21       Impact factor: 2.929

Review 4.  Role of RUNX1 in hematological malignancies.

Authors:  Raman Sood; Yasuhiko Kamikubo; Paul Liu
Journal:  Blood       Date:  2017-02-08       Impact factor: 22.113

Review 5.  Molecular pathogenesis and clinical management of Fanconi anemia.

Authors:  Younghoon Kee; Alan D D'Andrea
Journal:  J Clin Invest       Date:  2012-11-01       Impact factor: 14.808

Review 6.  Genetic predisposition to MDS: clinical features and clonal evolution.

Authors:  Alyssa L Kennedy; Akiko Shimamura
Journal:  Blood       Date:  2019-01-22       Impact factor: 22.113

7.  Single nucleotide polymorphism array analysis of bone marrow failure patients reveals characteristic patterns of genetic changes.

Authors:  Daria V Babushok; Hongbo M Xie; Jacquelyn J Roth; Nieves Perdigones; Timothy S Olson; Joshua D Cockroft; Xiaowu Gai; Juan C Perin; Yimei Li; Michele E Paessler; Hakon Hakonarson; Gregory M Podsakoff; Philip J Mason; Jaclyn A Biegel; Monica Bessler
Journal:  Br J Haematol       Date:  2013-10-14       Impact factor: 6.998

8.  Clonal hematopoiesis in patients with dyskeratosis congenita.

Authors:  Nieves Perdigones; Juan C Perin; Irene Schiano; Peter Nicholas; Jaclyn A Biegel; Philip J Mason; Daria V Babushok; Monica Bessler
Journal:  Am J Hematol       Date:  2016-10-21       Impact factor: 10.047

Review 9.  Fanconi anaemia and cancer: an intricate relationship.

Authors:  Grzegorz Nalepa; D Wade Clapp
Journal:  Nat Rev Cancer       Date:  2018-01-29       Impact factor: 60.716

10.  RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.

Authors:  V I Gaidzik; V Teleanu; E Papaemmanuil; D Weber; P Paschka; J Hahn; T Wallrabenstein; B Kolbinger; C H Köhne; H A Horst; P Brossart; G Held; A Kündgen; M Ringhoffer; K Götze; M Rummel; M Gerstung; P Campbell; J M Kraus; H A Kestler; F Thol; M Heuser; B Schlegelberger; A Ganser; L Bullinger; R F Schlenk; K Döhner; H Döhner
Journal:  Leukemia       Date:  2016-05-03       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.